RecruitingNot ApplicableNCT06274320

Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment

Investigation of the Effect of a 2 Weeks Lipikar Urea 30% Application Preceding a Planned Topical 5-FU 4% Actinic Keratoses Treatment on Efficacy of 5-FU 4%


Sponsor

Cosmetique Active International

Enrollment

100 participants

Start Date

Apr 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp
  • planned treatment of actinic keratoses of the scalp with Tolak®
  • Olsen grade I or II

Exclusion Criteria4

  • known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%
  • treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)
  • suspected invasive squamous cell cancer in the treatment area
  • chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGroup A: holistic approach

2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)

OTHERGroup B: Tolak® Standard of use

4-week Tolak® alone treatment (once daily in the evening)


Locations(1)

CentroDerm GmbH

Wuppertal, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06274320


Related Trials